Phase 1 Safety and Immunogenicity Evaluation of a Multiclade HIV‐1 Candidate Vaccine Delivered by a Replication‐Defective Recombinant Adenovirus Vector
Andrew Catanzaro(National Institutes of Health), Barney S. Graham(National Institutes of Health), Richard A. Koup(Aaron Diamond AIDS Research Center), C. Richter King(GenVec), Laura Novik(National Institutes of Health), Mary E. Enama(National Institutes of Health), Rebecca Sheets(National Institutes of Health), Robert T. Bailer(National Institutes of Health), John R. Mascola(National Institute of Allergy and Infectious Diseases), Bimal K. Chakrabarti(University of Vienna), Jason G. Gall(GenVec), Bryan T. Butman(GenVec), Phillip L. Gomez(National Institutes of Health), Mario Roederer(National Institutes of Health), Gary J. Nabel(National Institutes of Health), Julie E. Martin(National Institutes of Health), Zoe Moodie(Fred Hutch Cancer Center), Lin Gu(Shanghai Public Health Clinical Center), Charla Andrews(National Institutes of Health)
Cited by 318
Related Papers
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
|Science|2020|9.8k
A human memory T cell subset with stem cell–like properties
|Nature Medicine|2011|2k
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
|Science|2010|1.8k
Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation
|Journal of Immunological Methods|2003|1.6k